Ritter Pharmaceuticals Inc (RTTR) Given Average Recommendation of “Strong Buy” by Brokerages
Shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price target of $5.33 for the company, according to Zacks. Zacks has also given Ritter Pharmaceuticals an industry rank of 99 out of 265 based on the ratings given to related companies.
A number of research firms have issued reports on RTTR. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Maxim Group reiterated a “buy” rating on shares of Ritter Pharmaceuticals in a report on Tuesday, June 28th. Finally, Aegis reiterated a “buy” rating on shares of Ritter Pharmaceuticals in a report on Tuesday.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/ritter-pharmaceuticals-inc-rttr-given-average-recommendation-of-strong-buy-by-brokerages.html
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 14.35% during mid-day trading on Wednesday, hitting $2.63. The company’s stock had a trading volume of 2,267,801 shares. Ritter Pharmaceuticals has a 1-year low of $0.98 and a 1-year high of $3.00. The stock’s market cap is $22.58 million. The company has a 50-day moving average price of $1.60 and a 200-day moving average price of $1.55.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.14. Analysts predict that Ritter Pharmaceuticals will post ($1.38) EPS for the current fiscal year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.